Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Dermatomyositis

NCT05986162 is registered in ClinicalTrials.gov with Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05986162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05986162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Dermatomyositis
Lead sponsor
Biotech Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 30, 2023
Completion date
June 25, 2025
Enrollment
44 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, adult type